About
Orthonose is a physician-supervised 3D nasal platform that turns a facial scan into an agreed plan, then into a patient-matched surgical guide or night-worn interceptive care, for rhinoplasty surgeons and for parents of adolescents.
A surgeon scans the face, agrees the intended shape with the patient, and receives a printed guide for theatre. The guide is matched to that patient’s anatomy, so the operation follows the locked plan. 250+ patients have been operated with Orthonose guides.
For a nose that is still growing, the same scan and plan forecast the remaining growth. A physician can then order a night-worn orthosis, remade as the face changes, over a typical course of 24–36 mo. In the initial series, 4/4 treated patients had a mean hump change of −4 mm² against an expected +21 mm². 8/8 untreated kept growing. That series is small and non-randomized. Larger studies and follow-up through nasal maturity are still needed.
Both paths start from the same landmark-referenced 3D map and the same surgeon platform. What changes is the order: a printed guide per case, or a monthly interceptive plan.
Surgeons often plan from 2D photos and freehand morphs. Orthonose draws the plan on a sub-millimeter 3D map anchored to anatomical landmarks, and records the agreement before anything is made.
The printed guide seats on the scanned anatomy. Lattice openings leave the dorsum accessible while the reference stays in place. The physical shape is the proposal the patient agreed.
For adolescents there has been no standard of care that watches nasal growth the way orthodontics watches teeth. Interceptive care forecasts first, then a night-worn device under a physician, with surgery still available later on the same platform.
Orthonose invoices the seat, the printed guide, and the monthly interceptive plan. List prices excluding VAT: €200 a month for a solo seat, €1,500 a month for a clinic seat, €700 per printed guide, and interceptive care from €100 a month or €1,200 a year.
3 practising rhinoplasty surgeons in Paris are the first paying clients, billed for commercial use. This is not a pilot and not a grant. 6 patents are granted, in the US, Europe, Canada, China, Brazil, and Israel, with the European patent validated across eleven states. CE Class I and IIa in Europe; ANSM declaration filed. Patient-specific.
Orthonose SAS is in Paris. The method was built by the clinicians who invented it.
Dr. Yaël Berdah is co-founder and chief medical officer. Dr. Marc-David Benjoar is co-founder and chief technology officer.
Kristoffer Laurson is chief executive officer.
Benjamin Barbier-Aknin chairs the board and is general counsel. Carine Berdah leads finance. Prof. Laurent Lantieri advises on the growth forecast. A chief commercial officer is being hired for Paris and Dubai.
A surgeon or a parent writes for a first conversation. No patient images are required. For a surgeon, onboarding is capture training, then the first guide from plan to order to theatre, then a case review with the outcome on the record.
Contact
Orthonose is a physician-supervised 3D nasal platform. A scan becomes a shared plan, then either a patient-matched surgical guide or night-worn interceptive care. CE Class I and IIa in Europe; ANSM declaration filed. Patient-specific.
CE Class I and IIa in Europe; ANSM declaration filed. Patient-specific. The ANSM step is a declaration filed, not an approval.
No. The orthosis is worn at night and is not taken into the operating room. A physician stays in charge from the first scan through follow-up. The early series is preliminary: 4/4 treated, mean −4 mm² versus an expected +21 mm², and 8/8 untreated kept growing.
A platform seat, a printed guide per surgical case, or a monthly interceptive plan. The surgeon keeps the procedure fee. List prices excluding VAT are €200 a month solo, €1,500 a month for a clinic, €700 per guide, and interceptive care from €100 a month or €1,200 a year.
The public inbox. A first conversation does not need patient images. Contact